Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Pharmaceuticals Secures USD $1.9 Million Sales Contract for SmoothX 2% (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Healthcare
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more

Recent & Breaking News (NYSE:TAK)

OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines

PR Newswire November 11, 2020

Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting

Business Wire November 9, 2020

Eligible patients living with rare debilitating genetic disorder are one step closer to having access to first-of-its-kind treatment option

Canada NewsWire November 5, 2020

Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting

Business Wire November 5, 2020

Seqster Partners with Takeda to Help Digitally Transform Patient Experiences

PR Newswire October 29, 2020

Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS

Business Wire October 29, 2020

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

Business Wire October 29, 2020

Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020

Business Wire October 27, 2020

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Nebraska

Business Wire October 21, 2020

Takeda Accelerates Digital Transformation with Accenture and AWS

Business Wire October 13, 2020

Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis

Business Wire October 12, 2020

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

Business Wire October 8, 2020

Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda's Late-Stage Lung Cancer Portfolio

Business Wire September 18, 2020

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

Business Wire September 18, 2020

Takeda to Divest TachoSil® to Corza Health for Euro350 Million

Business Wire September 16, 2020

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

Business Wire September 15, 2020

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Metropolitan Detroit

Business Wire September 11, 2020

Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO(TM) (ixazomib) in Newly Diagnosed Multiple Myeloma

Business Wire September 9, 2020

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

Business Wire September 8, 2020

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

Business Wire August 25, 2020